The bare skin and the nose as non-invasive routes for administering peptide vaccines

Vaccine

Volumn 19, Issue 17-19, 2001, Pages 2708-2715

  Partidos, Charalambos D ^a   Beignon, Anne Sophie ^a   Semetey, Vincent ^a   Briand, Jean Paul ^a   Muller, Sylviane ^a  

^a INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Intranasal immunisation; Skin immunisation; Synthetic vaccine

Indexed keywords

ANTIGEN; BETA GALACTOSIDASE; CHOLERA TOXIN; CYCLOPEPTIDE; DNA VACCINE; ESCHERICHIA COLI ENTEROTOXIN; INFLUENZA VACCINE; INTERLEUKIN 12; ISCOM; LIPOSOME; MEASLES VACCINE; OLIGODEOXYNUCLEOTIDE DERIVATIVE; PSEUDOPEPTIDE; QUIL A; SYNTHETIC PEPTIDE; VACCINE;

ANTIGEN PRESENTING CELL; ANTIGENICITY; CHEMICAL COMPOSITION; CONFERENCE PAPER; DEVELOPING COUNTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG STRUCTURE; FOOT DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; LYMPHOID TISSUE; MEASLES; MOUTH DISEASE; MUCOSAL IMMUNITY; NONHUMAN; NOSE; PRIORITY JOURNAL; PROTEIN TRANSPORT; SKIN; VACCINATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRANASAL; AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; ANTIGEN PRESENTATION; HUMANS; IMMUNITY, MUCOSAL; MICE; PEPTIDES; VACCINES, SUBUNIT;

EID: 0035925685     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00507-7     Document Type: Article

References (50)

1. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: Model-based regional estimates
2. The role of nasopharyngeal lymphoid tissue
3. The skin immune system. Its cellular constituents and their interactions
4. The mucosal immune system: From fundamental concepts to vaccine development
5. Transcutaneous immunisation with bacterial ADP-ribosylating exotoxins as antigens and adjuvants
6. Synthetic approaches to vaccines for infectious and autoimmune diseases
7. Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence
8. Antibodies against a preselected peptide recognize and neutralize foot-and-mouth disease virus
9. Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics
10. Exploration of requirements for peptidomimetic immune recognition. Antigenic and immunogenic properties of reduced peptide bond pseudopeptide analogues of histone hexapeptide
11. A retro-inverso peptide corresponding to the GH loop of foot-and-mouth disease virus elicits high levels of long-lasting protective neutralizing antibodies
12. Protection against lymphocytic choriomeningitis virus infection induced by a reduced peptide bond analogue of the H-2Db-restricted CD8(+) T cell epitope gp33
13. Recent developments in retro-inverso peptides and proteins. An ongoing topochemical exploration
14. A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis
15. Protection of swine from foot-and mouth disease with one dose of an all-D retro peptide
16. A partially modified retro-inverso pseudopeptide modulates the cytokine profile of CTL specific for an influenza virus epitope
17. In vivo T helper cell response to retro-inverso peptidomimetics
18. Solution structure of a retro-inverso analogue mimicking the foot-and-mouth disease virus major antigenic site. Structural basis for its antigenic cross-reactivity with the parent peptide
19. Structural limitations to antigenic mimicry achievable with retro-inverso (all-D-retro) peptides
20. Pseudopeptide ligands for MHC II-restricted T cells
21. Solid-phase synthesis of N, N′-unsymmetrically substituted ureas: Application to the synthesis of carbaza peptides
22. Melanoma-peptide MART-1 (27-35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue. Implications for recognition by tumor infiltrating lymphocytes
23. Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules
24. Induction of systemic immune responses to measles virus synthetic peptides administered intranasally
25. Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunisation with synthetic peptides
26. Induction of antigen specific antibodies in vagina secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant
27. The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunisation with a synthetic peptide
28. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A
29. CpG motifs in bacterial DNA trigger direct B cell activation
30. CpG-rich islands and the function of DNA methylation
31. CpG DNA is a potent enhancer of specific immunity in mice immunised with recombinant hepatitis B surface antigen
32. Anti-peptide antibody responses following intranasal immunisation: Effectiveness of mucosal adjuvants
33. Antigenic properties and protective capacity of a cyclic peptide corresponding to site A of influenza virus haemagglutinin
34. Activation of human B cells by phosphorothioate oligodeoxynucleotides
35. Liposomes as carriers of peptide antigens: Induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides
36. Linkage of a fusion peptide to a CTL epitope from the nucleoprotein of measles virus enables incorporation into ISCOMs and induction of CTL responses following intranasal immunisation
37. Intranasal immunisation of mice against influenza with synthetic peptides anchored to proteosomes
38. Mucosal immunisation with a measles virus CTL epitope encapsulated in biodegradable PLG microparticles
39. The skin as a barrier: Structure and function
40. The Langerhans cell: Antigen processing/antigen presentation
41. Role of cytokines in epidermal Langerhans cell migration
42. Acute cutaneous barrier perturbation induces maturation of Langerhans cells in hairless mice
43. Cutaneous vaccination: The skin as an immunologically active tissue and the challenge of antigen delivery
44. Vaccination onto bare skin
45. Immunization via hair follicles by topical application of naked DNA to normal skin
46. Effects of IL-12 on immune responses induced by transcutaneous immunization with antigens formulated in a novel lipid-based biphasic delivery system
47. Needle-free, non-adjuvanted skin immunization by electroporation-enhanced transdermal delivery of diphteria toxoid and a candidate peptide vaccine against hepatitis B virus
48. Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transferosomes
49. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal challenge
50. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis